Provided by Tiger Trade Technology Pte. Ltd.

Spring Bank Pharmaceuticals

1.21
0.0000
Volume:- -
Turnover:- -
Market Cap:5.22M
PE:-0.18
High:1.21
Open:1.21
Low:1.21
Close:1.21
52wk High:19.20
52wk Low:1.21
Shares:4.32M
Float Shares:3.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5410
EPS(LYR):-5.8580
ROE:-90.61%
ROA:-33.74%
PB:0.29
PE(LYR):-0.21

Loading ...

Company Profile

Company Name:
Spring Bank Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.